PROLOR Biotech To Present At Oppenheimer 23rd Annual Healthcare Conference
NES-ZIONA, Israel, Dec. 10, 2012
NES-ZIONA, Israel, Dec. 10, 2012 /PRNewswire/ --PROLOR Biotech, Inc. (NYSE
MKT:PBTH) today announced that company management will give a corporate
presentation at the Oppenheimer 23^rd Annual Healthcare Conference on December
12, 2012 at 9:25 am EST. The conference is being held December 12-13, 2012
at the Waldorf Astoria Hotel in New York City.
A live webcast of the company's presentation will be available at
archived version of the webcast will be available for 90 days beginning about
three hours after the live presentation.
For more information about the Oppenheimer 23^rd Annual Healthcare Conference,
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology and its long-acting
reversible-pegylation technology, primarily to develop longer-acting
proprietary versions of already approved therapeutic proteins that currently
generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a long-acting
version of human growth hormone, which successfully completed a Phase II
clinical trial. It also is developing long-acting versions of Factor VIIa and
Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide
for diabetes and obesity, all of which are in preclinical development. For
more information, visit www.prolor-biotech.com.
PROLOR CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
PROLOR Biotech, Inc. BLL Partners, LLC
Tel: +1 866 644-7811 +1 212 584-2276
Email: firstname.lastname@example.org email@example.com
SOURCE PROLOR Biotech, Inc.
Press spacebar to pause and continue. Press esc to stop.